RethinkPeptides
Peptide Vaccines for Infectious Disease

Peptide Vaccines for HIV: Decades of Failure and New Hope

14 min read|March 25, 2026

Peptide Vaccines for Infectious Disease

31% risk reduction

The only HIV vaccine trial to show any efficacy: RV144 in Thailand, where V1V2-targeted IgG antibodies against gp120 peptide epitopes correlated with reduced infection risk.

RV144 Trial, Rerks-Ngarm et al., NEJM, 2009

RV144 Trial, Rerks-Ngarm et al., NEJM, 2009

Diagram showing HIV envelope peptide epitopes targeted by vaccine-induced antibodiesView as image

HIV has defeated every vaccine candidate tested in efficacy trials for over four decades. The virus mutates rapidly, hides its vulnerable surfaces behind sugar molecules, and destroys the very immune cells that vaccines rely on to build memory. Peptide-based approaches have been central to this effort from the beginning because the HIV envelope proteins (gp120 and gp41) are the primary vaccine targets, and peptide epitopes from these proteins are what antibodies must recognize. One trial, RV144 in Thailand, showed a modest 31% reduction in infection risk, with V1V2 peptide-specific antibodies correlating with protection. Every other efficacy trial has failed. The field has now shifted to germline-targeting strategies that use peptide immunogens to guide naive B cells through a multi-step process toward broadly neutralizing antibodies. Early clinical data from 2025 shows this approach works in humans. For broader context on peptide vaccine technology, see Peptide-Based COVID Vaccine Candidates: What Made It to Trials.

Key Takeaways

  • RV144 remains the only HIV vaccine trial showing any efficacy (31% risk reduction), with IgG antibodies targeting gp120 V1V2 peptide regions correlating with reduced infection
  • The STEP, Phambili, and HVTN 505 trials all failed, with some showing increased infection risk in vaccine recipients
  • Enfuvirtide (T-20), a 36-amino acid peptide that blocks gp41-mediated viral fusion, proved that peptides can target HIV entry but is used as treatment, not prevention[2]
  • A gp41 peptide-liposome vaccine elicited neutralizing epitope-targeted antibodies in healthy individuals in a 2025 clinical trial[7]
  • Germline-targeting vaccines using mRNA-encoded peptide immunogens activated rare bnAb precursor B cells in Phase 1 trials (IAVI G001, G002, G003)
  • HIV's extreme genetic diversity, glycan shielding, and immune evasion explain why peptide epitopes that work in vitro fail to protect in vivo

Why HIV Defeats Peptide Vaccines

HIV presents three problems that no other virus combines to this degree:

Genetic diversity. HIV mutates at a rate of roughly one error per genome per replication cycle. Within a single infected person, the virus diversifies into a swarm of related but distinct variants (a quasispecies). A vaccine targeting one peptide sequence may encounter a virus whose corresponding sequence has already changed.

Glycan shielding. The HIV envelope protein gp120 is coated with host-derived sugar molecules (glycans) that mask the underlying peptide epitopes from antibodies. The conserved regions that antibodies need to reach are hidden behind this "glycan shield." Antibodies that can penetrate this shield, called broadly neutralizing antibodies (bnAbs), are rare and take years of chronic infection to develop naturally.

Immune evasion. HIV infects and kills CD4+ T helper cells, the very cells that coordinate the adaptive immune response. A vaccine must generate immunity before exposure, because once HIV establishes infection, it dismantles the immune machinery needed to fight it.

These features explain a consistent pattern: peptide epitopes from HIV envelope proteins generate antibodies in clinical trials that bind the immunogen but fail to neutralize diverse circulating viral strains.

The History of HIV Vaccine Failures

VAX003 and VAX004 (2003)

These Phase 3 trials tested recombinant gp120 proteins (AIDSVAX) designed to elicit antibodies against the HIV envelope. Neither trial showed efficacy. Antibodies were generated but could not neutralize diverse HIV strains. The gp120 proteins used did not present the epitopes in the conformation needed for neutralizing antibody induction.

STEP and Phambili (2007-2009)

These trials used an adenovirus vector (Ad5) carrying HIV genes (gag, pol, nef), not envelope peptides, aiming to generate T cell responses rather than antibodies. The STEP trial was stopped early when vaccinated men with pre-existing Ad5 antibodies showed increased HIV infection rates. Phambili confirmed this signal.

HVTN 505 (2013)

A DNA prime/Ad5 boost strategy targeting multiple HIV genes showed no efficacy and was stopped for futility after interim analysis.

RV144: The One Positive Signal (2009)

The Thai trial tested a prime-boost strategy: ALVAC-HIV (canarypox vector with gp120 insert) as the prime and AIDSVAX gp120 as the boost. At 3.5 years, vaccine recipients had a 31% lower rate of HIV infection than placebo recipients. The effect was modest, borderline significant, and waned over time.

The correlates analysis was the breakthrough. IgG antibodies targeting the V1V2 loop of gp120 correlated with reduced infection risk. IgA antibodies against gp120, conversely, correlated with increased risk, suggesting they competed with protective IgG for binding. This finding directed subsequent peptide vaccine research toward V1V2-targeted antibody responses specifically.

HVTN 702 (2020)

An attempt to improve on RV144 using a similar strategy adapted for South African HIV subtypes was stopped for futility. The vaccine showed no efficacy.

Enfuvirtide: The Peptide That Works Against HIV (But Not as a Vaccine)

While vaccines failed, one HIV peptide drug succeeded. Enfuvirtide (T-20, brand name Fuzeon) is a 36-amino acid synthetic peptide that mimics a region of gp41, the transmembrane envelope protein that mediates viral-cell membrane fusion.

Wild and colleagues (1994) first demonstrated that peptides corresponding to the alpha-helical domain of gp41 potently inhibited HIV infection by blocking the conformational change required for membrane fusion.[1] Kilby and colleagues (1998) showed that T-20 achieved potent HIV suppression in humans, reducing viral load by 1.5-2.0 log10 copies/mL.[2]

Enfuvirtide was approved in 2003 for treatment-experienced HIV patients. Cooper and colleagues (2004) reviewed its clinical development as a case study in peptide drug discovery.[3] It proved that peptides can effectively target HIV entry, but twice-daily subcutaneous injections and injection site reactions limited its use. Pu and colleagues (2019) reviewed the broader landscape of protein and peptide HIV entry inhibitors targeting both gp120 and gp41.[4]

Enfuvirtide's success as a therapeutic peptide contrasts with the failure of peptide vaccines: blocking a single molecular interaction with a high concentration of peptide at the cell surface is achievable, but training the immune system to produce the right antibodies against the right epitopes in the right conformation is a fundamentally harder problem.

Germline-Targeting: The New Strategy

The field has converged on a radically different approach. Instead of presenting HIV peptide epitopes and hoping for neutralizing antibodies, germline-targeting vaccines are designed to find and activate the specific rare naive B cells whose antibody genes are precursors to bnAbs, then guide them through a multi-step maturation process.

The concept: bnAbs against HIV are extraordinarily rare (found in roughly 10-30% of chronically infected individuals after years of infection). They have unusual features: very long CDRH3 loops, extensive somatic hypermutation, and the ability to penetrate the glycan shield. These antibodies cannot be generated by a single vaccination. They require sequential immunizations with a series of designed immunogens that progressively shape the antibody response from germline precursor to mature bnAb.

IAVI G001 (2021)

This Phase 1 trial tested eOD-GT8 60mer, an engineered protein nanoparticle designed to activate VRC01-class bnAb precursor B cells. In 36 healthy volunteers, the vaccine activated the target germline B cells in 97% of recipients, proving the first step of the strategy works in humans.

IAVI G002 and G003 (2025)

Published in Science in May 2025, these trials tested mRNA-encoded versions of the germline-targeting immunogen. G002 (60 participants in North America) and G003 (18 participants in South Africa and Rwanda) showed that mRNA delivery produced strong immune responses. Critically, G002 tested a heterologous boost strategy with a different immunogen designed to advance the antibody response from the germline activation stage to the next maturation step. The results demonstrated that the sequential immunization approach guides antibody maturation in humans.

These are not peptide vaccines in the traditional sense (they use mRNA to encode protein immunogens), but the immunogens themselves are designed around specific peptide epitopes from the HIV envelope, and the antibody responses they aim to elicit target peptide-defined epitopes on gp120 and gp41.

Peptide-Liposome Vaccines: A Direct Approach

Erdmann and colleagues (2025) reported results from a clinical trial of a gp41 peptide-liposome vaccine in healthy individuals. The vaccine used synthetic peptides from the membrane-proximal external region (MPER) of gp41, a conserved region targeted by several known bnAbs, conjugated to liposomes to enhance immunogenicity.[7]

The vaccine elicited antibodies targeting the MPER neutralizing epitope in vaccinated individuals. This is one of the first demonstrations that a peptide-based HIV vaccine can induce antibodies directed at a known bnAb epitope in humans. Whether these antibodies are potent enough to prevent infection is unknown; no efficacy trial has been conducted.

The MPER region is a challenging target because it sits at the membrane interface, partially embedded in the viral lipid bilayer. Antibodies targeting MPER must interact with both the peptide and the surrounding lipid environment. This may explain why MPER-directed bnAbs often cross-react with self-lipids, raising autoimmunity concerns.

Technical Challenges Specific to HIV Peptide Vaccines

Dacoba and colleagues (2020) reviewed the technological challenges in HIV nanovaccine development, identifying several barriers specific to peptide-based approaches:[5]

Conformational fidelity. HIV envelope peptides must be presented in the exact three-dimensional conformation they adopt on the native viral trimer. Linear peptides or peptides in the wrong conformation generate antibodies that bind the immunogen but not the virus.

Adjuvant requirements. Peptide immunogens are inherently weak antigens. They require potent adjuvants or delivery platforms (nanoparticles, liposomes, mRNA) to generate sufficient immune responses.

Epitope masking. The glycan shield and conformational dynamics of the HIV envelope mean that conserved peptide epitopes are exposed only transiently. Antibodies must reach these epitopes during the brief windows when they are accessible.

Zhu and colleagues (2021) demonstrated that pan-coronavirus fusion inhibitor peptides also possessed potent activity against HIV-1 and HIV-2, suggesting that conserved viral fusion mechanisms could be targeted across virus families.[6]

Peptide Delivery Innovations for HIV

Cell-penetrating peptides and other delivery technologies are being applied to improve HIV vaccine candidates.

Gheydi and colleagues (2025) demonstrated efficient non-viral delivery of an HIV-1 Nef-Tat DNA construct using the CM18-TAT11 cell-penetrating peptide, showing that CPPs can deliver vaccine constructs into antigen-presenting cells to enhance immune priming.[8]

Maani and colleagues (2024) reviewed the HIV-derived TAT peptide itself as a molecular shuttle for drug delivery, demonstrating the ironic utility of an HIV-derived peptide as a tool for biomedical applications beyond HIV.[9]

Tajvidi and colleagues (2026) enhanced the efficiency of a DNA vaccine construct by linking it to IL-7 cytokine and a REV peptide, showing that peptide components can boost both the delivery and immunogenicity of HIV vaccine constructs.[10]

What Four Decades of Failure Have Taught

The HIV vaccine field has learned more from failure than from any other area in vaccinology:

  1. Antibody binding is not antibody neutralization. Every failed vaccine generated antibodies. None generated antibodies capable of neutralizing diverse circulating HIV strains.

  2. Strain-matched immunity is insufficient. HIV diversity means that even perfect immunity against the vaccine strain leaves people vulnerable to the thousands of other circulating variants.

  3. The immune system needs guidance. BnAbs do not arise spontaneously from a single vaccination. They require a guided maturation process that takes multiple sequential immunizations with carefully designed immunogens.

  4. Peptide conformation matters as much as sequence. The same peptide sequence presented in different conformations generates different antibodies. Only antibodies matching the native trimer conformation are protective.

  5. Correlates of protection exist but are narrow. RV144 showed that V1V2-targeted IgG (not IgA) correlates with reduced risk. This specificity has redirected the entire field.

These lessons apply beyond HIV to all peptide vaccine development, including vaccines for cancer, influenza, and emerging pathogens. For how peptide vaccine design works in principle, see CMV Peptide Vaccines: Protecting Transplant Patients and the broader infectious disease vaccine landscape.

The Bottom Line

Four decades of HIV peptide vaccine research have produced one modestly efficacious trial (RV144, 31% risk reduction), one approved therapeutic peptide (enfuvirtide), and a new generation of germline-targeting vaccines that showed their first positive human data in 2025. The gp41 peptide-liposome vaccine represents a direct peptide approach that elicited bnAb-epitope-targeted antibodies in healthy volunteers. HIV's genetic diversity, glycan shielding, and immune evasion explain why peptide epitopes that work in isolation fail against the whole virus. The field has shifted from designing peptides that look like HIV to designing immunogens that guide the immune system through a multi-step process toward broadly neutralizing antibodies.

Frequently Asked Questions